Core Viewpoint - The article provides insights into the latest stock holdings and trading activities of major institutional investors in the A-share market, focusing on the Social Security Fund, QFII, and public funds, highlighting their preferences and adjustments in stock positions during the first quarter of 2025 [2][3][8][13]. Social Security Fund Holdings - As of the end of Q1 2025, the Social Security Fund was involved in 597 listed companies, with a total holding of 10.913 billion shares, a year-on-year decrease of 11.26%, and a total market value of 173.945 billion yuan, down 6.43% year-on-year [3]. - The fund's investments in sectors such as machinery, basic chemicals, electronics, non-ferrous metals, electric equipment, and pharmaceuticals exceeded 13 billion yuan, with the pharmaceutical sector having the highest number of holdings at 61 companies [3]. - The top 50 companies held by the Social Security Fund accounted for 66.579 billion yuan, representing 38.28% of its total holdings, with SANY Heavy Industry leading at 3.352 billion yuan [3][4]. QFII Holdings - By the end of Q1 2025, QFII held shares in 692 listed companies, a decrease of 3.76% year-on-year, with a total market value of 117.213 billion yuan, an increase of 11.5% year-on-year [8]. - Notably, two companies, Ningbo Bank and Nanjing Bank, had QFII holdings exceeding 10 billion yuan, with values of 32.17 billion yuan and 19.264 billion yuan, respectively [10]. - QFII's investments were concentrated, with the top 50 stocks accounting for 81.02% of its total holdings [8]. Fund Holdings - The public fund holdings report indicated that 51 stocks had a market value exceeding 10 billion yuan, with Ningde Times and Kweichow Moutai leading at 146.823 billion yuan and 141.539 billion yuan, respectively [13][16]. - The number of funds holding Ningde Times reached 1,864, while Kweichow Moutai had 1,196 funds, both showing significant growth [13]. - Other notable companies with substantial fund holdings included China Merchants Bank, Midea Group, and Ping An Insurance, each exceeding 50 billion yuan [17]. Market Outlook - Fund managers expressed optimism about the A-share market, citing strong economic resilience and potential recovery signals, particularly in consumer sectors [14].

证券代码：600426 证券简称：华鲁恒升 公告编号：临 2025-027 山东华鲁恒升化工股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 29 日 (二)股东大会召开的地点：山东省德州市经济开发区东风东路 2555 号凤冠假日 酒店 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 680 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 869,166,797 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 40.9362 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董 事会召集，董事长常怀春先生主持。会议的召集、召开符合 ...

证券代码：600426 证券简称：华鲁恒升 编号：临 2025-028 山东华鲁恒升化工股份有限公司 关于回购股份注销减少注册资本通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原因 山东华鲁恒升化工股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日、2025 年 4 月 29 日分别召开了第九届董事会 2025 年第 2 次临时会议、2024 年年度股东大会， 审议通过了《关于以集中竞价交易方式回购公司部分股份方案的议案》。同意公司自股 东大会审议通过之日起 12 个月内使用不低于人民币 20,000.00 万元（含），不高于人 民币 30,000.00 万元（含）的自有资金或自筹资金，通过集中竞价交易方式以不超过人 民币 32.38 元/股（含）的价格回购公司股份，本次回购股份将全部予以注销并减少公 司注册资本。 上述回购方案及股东大会决议内容详见公司分别于 2025 年 4 月 18 日、2025 年 4 月 30 日在上海证券交易所网站（www.sse.com.c ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东华鲁恒升化工股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]A0141 号 致：山东华鲁恒升化工股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券 法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证 券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东华鲁恒升 化工股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与 召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company [2][4]. Core Views - The company reported a revenue of 7.772 billion yuan in Q1 2025, a year-on-year decrease of 2.59%, and a net profit attributable to shareholders of 707 million yuan, down 33.65% year-on-year. The decline in product prices has negatively impacted overall revenue growth [3]. - Despite the challenges, the company is actively advancing project construction, which is expected to provide new momentum for future development. Key projects include the melamine resin optimization project and the nylon 66 high-end new materials project, which are set to enhance production capacity [4]. - The company is projected to achieve net profits of 4.008 billion yuan, 4.587 billion yuan, and 5.351 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 1.89 yuan, 2.16 yuan, and 2.52 yuan. The current stock price corresponds to P/E ratios of 11, 9, and 8 times for the same years [4]. Financial Performance Summary - In Q1 2025, the company's main products, including urea, isooctanol, nylon 6, and others, experienced a decline in prices, leading to a comprehensive gross margin decrease of 5.54 percentage points to 16.35% [3]. - The company’s revenue and profit forecasts for 2025-2027 indicate a gradual recovery, with revenue expected to grow from 36.405 billion yuan in 2025 to 45.073 billion yuan in 2027, reflecting a growth rate of 6.37% and 12.01%, respectively [5]. - The company’s net profit is projected to grow at rates of 2.71%, 14.44%, and 16.65% for the years 2025, 2026, and 2027, respectively [5].

Investment Rating - The investment rating for the company is "Buy" [3] Core Views - The company reported Q1 2025 revenue of 7.77 billion yuan, a year-over-year decrease of 3% and a quarter-over-quarter decrease of 14%. The net profit attributable to shareholders was 710 million yuan, down 34% year-over-year and 17% quarter-over-quarter [1][3] - The company is a leading player in the coal chemical industry in China, with a significant low-cost moat. The extension of the industrial chain and product expansion at the Jingzhou base are expected to drive steady growth in performance. Projected net profits for 2025-2027 are 4.036 billion, 4.666 billion, and 5.120 billion yuan, with year-over-year growth rates of 3.41%, 15.62%, and 9.73%, respectively [3][4] - The company is experiencing pressure on profitability due to product price declines, but cost reductions are expected to improve product price differentials in Q2, driven by industry recovery [8][9] Financial Summary - For 2025, the company is expected to achieve revenue of 37.041 billion yuan, with a year-over-year growth of 8.22%. The net profit is projected to be 4.036 billion yuan, reflecting a year-over-year growth of 3.41% [4][9] - The company's earnings per share (EPS) for 2025 is estimated at 1.90 yuan, with a price-to-earnings (P/E) ratio of 10.59 [4][9] - The company’s gross margin and net margin for Q1 2025 were 16.3% and 9.9%, respectively, indicating a decline in profitability due to lower product prices [8][9]

Group 1 - The Shanghai Composite Index opened lower and the CSI 300 Chemical Index reported 2064.08 points, with a decline of 7.57% in the last month, 6.98% in the last three months, and 6.77% year-to-date [1] - The CSI 300 Index is categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries, providing a comprehensive analysis tool for investors [1] - The top ten weights in the CSI 300 Chemical Index are: Wanhua Chemical (23.08%), Salt Lake Industry (13.6%), Baofeng Energy (7.79%), Juhua Co. (7.6%), Hengli Petrochemical (7.22%), Satellite Chemical (6.88%), Hualu Hengsheng (6.64%), Zangge Mining (6.38%), Longbai Group (6.1%), and Rongsheng Petrochemical (5.49%) [1] Group 2 - In terms of industry composition within the CSI 300 Chemical Index, other chemical raw materials account for 39.09%, polyurethane for 23.08%, potassium fertilizer for 19.98%, fluorochemical for 7.60%, titanium dioxide for 6.10%, and organic silicon for 4.15% [2] - The index sample is adjusted biannually, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to changes in the CSI 300 Index samples or significant events affecting sample companies [2]

Core Insights - The social security fund has invested in 478 stocks by the end of Q1, with 46 stocks held for over 20 consecutive quarters [1] - The fund's long-term holdings include 257 stocks held for more than four quarters, with 169 stocks held for over two years [1] - Notable long-term holdings include China Overseas Land & Investment, Zhongnan Media, and others, with the longest-held stock being China Overseas Land & Investment since Q2 2011 [1] Holdings Overview - The top holdings by quantity include Changshu Bank (254 million shares), Hualu Hengsheng (122 million shares), and China Jushi (84.52 million shares) [2] - The highest holding percentages are Changshu Bank (8.42%), Hualu Hengsheng (5.77%), and Keri International (5.70%) [2] - Among the 46 stocks, 12 saw an increase in holdings, with significant increases for Huayu Automotive (62.65%), Hualu Hengsheng (19.18%), and Yanjinpuzi (17.90%) [2] Performance Analysis - Of the 46 stocks, 28 reported year-on-year profit growth, with notable increases from Xiantan Co. (583.83%), Zhongyuan Media (234.61%), and China Jushi (108.52%) [3] - Conversely, 17 stocks experienced profit declines, with the largest decreases from Tianrun Dairy (-1713.36%), China Overseas Land & Investment (-303.09%), and Zhongqi Co. (-245.04%) [3] - Stocks with consistent profit growth over the past three years include Aide Biology, Yutong Bus, and Blue Sky Technology [3] Industry Distribution - The 46 stocks are concentrated in industries such as basic chemicals (6 stocks), automotive (5 stocks), and pharmaceutical biology (5 stocks) [2] - The main board contains 30 stocks, while the ChiNext board has 15 stocks, and the Sci-Tech Innovation board has 1 stock [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - In Q1 2025, the company achieved revenue of 7.772 billion yuan, a year-on-year decrease of 2.59%, and a net profit attributable to shareholders of 707 million yuan, down 33.65% year-on-year and 17.20% quarter-on-quarter. Despite most product price spreads being at historical lows, the company's net profit only declined by 1.47 billion yuan quarter-on-quarter, demonstrating strong performance resilience. The company announced a share buyback at a low market value, reflecting confidence in future development. The profit forecasts for 2025-2027 are maintained at 4.275 billion, 5.003 billion, and 5.760 billion yuan, with corresponding EPS of 2.01, 2.36, and 2.71 yuan per share, leading to PE ratios of 10.0, 8.5, and 7.4 times respectively. The company is expected to benefit from domestic policy support for demand recovery and falling coal prices, leading to a positive outlook for performance recovery [7][9]. Financial Summary - In Q1 2025, the average price of main products such as urea, acetic acid, and others showed a decline, with average prices of 1,727, 2,902, and 8,063 yuan per ton respectively, reflecting decreases of 3.40%, 2.07%, and 2.09% quarter-on-quarter. The average price spreads for these products were at historical low percentiles, indicating cost advantages and performance resilience for the company [8][9]. - The financial summary indicates that the company expects revenues of 32.107 billion yuan in 2025, with a year-on-year decrease of 6.2%. The net profit is projected to be 4.275 billion yuan, reflecting a year-on-year increase of 9.5%. The gross margin is expected to be 19.7%, and the net margin is projected at 13.6% [10][12].

事件评论 事件描述 公司发布2025 一季报，2025Q1 实现收入77.7 亿元（同比-2.6%，环比-14.1%），实现归属净利润7.1 亿 元（同比-33.7%，环比-17.2%），实现归属扣非净利润7.0 亿元（同比-34.2%，环比-13.3%）。 公司具备领先的生产工程化能力，产品具备显著的成本优势，德州本部与荆州基地拟投项目支撑未来发 展，多元化产品组合，一定程度上或将平移经营波动。预计2025-2027 年归属净利润分别为 37.2/41.6/47.0 亿元，维持"买入"评级。 风险提示 1、下游需求恢复不及预期； 2、新项目进度低于预期。 一季度景气回落产品销量有所回落，季度业绩环比有所下滑。价格，公司主要产品25Q1市场价格环比 变化：尿素（-2.5%）、DMF（-1.7%）、己二酸（-2.1%）、醋酸（1.9%）、辛醇（-12.4%）、己内酰 胺（-3.8%）、尼龙6（-6.3%）、三聚氰胺（-10.7%）、DMC（-14.2%）、草酸（-6.5%）。销售， 24Q4 公司荆州基地52 万吨/年尿素产能投产放量，25Q1 有机胺系列产品、化学肥料、醋酸及衍生品、 新能源新材料相关产品销量 ...